Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
51,6 USD | -0,73 % | -.--% | +12,17 % |
10.05. | Futures im Aufwind; Mib startet wieder bei 34.300 | AN |
09.05. | Mib im Plus, Nexi und Prysmian legen nach Bilanz zu | AN |
Kurzporträt
- Pharmazeutische und rezeptfreie Produkte (67,9%): für die Behandlung von Virusinfektionen, kardiovaskulären, dermatologischen, gynäkologischen Erkrankungen usw.;
- Arzneimittel für seltene Krankheiten (32,1%).
Der Nettoumsatz verteilt sich geographisch wie folgt: Italien (15%), Europa (58,5%), Amerika (17,5%), Australasien (6,2%) und Afrika (2,8%).
Mitarbeiterzahl: 4 455
Umsatz nach Geschäftsbereich
EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Specialty & Primary Care
65,7
%
| 1 258 | 67,9 % | 1 368 | 65,7 % | +8,75 % |
Rare Diseases
34,3
%
| 596 | 32,1 % | 715 | 34,3 % | +19,96 % |
Umsatz je Region
EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Europe
56,4
%
| 1 084 | 58,5 % | 1 175 | 56,4 % | +8,37 % |
America
19,0
%
| 324 | 17,5 % | 395 | 19,0 % | +22,06 % |
Italy
15,2
%
| 277 | 15,0 % | 317 | 15,2 % | +14,36 % |
Australasia
6,7
%
| 115 | 6,2 % | 140 | 6,7 % | +21,69 % |
Africa
2,7
%
| 53 | 2,9 % | 56 | 2,7 % | +3,96 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 01.12.21 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 01.11.19 |
Andrea Recordati
CHM | Chairman | 52 | 29.04.98 |
Raffaele Sabia
CTO | Chief Tech/Sci/R&D Officer | - | 01.07.17 |
Guido Guidi
BRD | Director/Board Member | 71 | 29.04.20 |
Investor Relations Contact | 51 | 01.10.20 | |
General Counsel | - | 01.04.23 | |
Bibianne Bon
LAW | General Counsel | - | 01.04.23 |
Human Resources Officer | - | 01.01.23 | |
Gabriele Finzi
PRN | Corporate Officer/Principal | - | 01.01.08 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 12.06.18 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 01.12.21 |
Andrea Recordati
CHM | Chairman | 52 | 29.04.98 |
Giorgio de Palma
BRD | Director/Board Member | 49 | 29.04.20 |
Elisa Corghi
BRD | Director/Board Member | 51 | 29.04.22 |
Director/Board Member | 56 | 29.04.20 | |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 01.11.19 |
Director/Board Member | 53 | 17.04.14 | |
Guido Guidi
BRD | Director/Board Member | 71 | 29.04.20 |
Director/Board Member | 60 | 05.02.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 209 125 156 | 97 110 939 ( 46,44 %) | 2 763 813 ( 1,322 %) | 46,44 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
RECORDATI 1,80% | 3 765 552 | 1,80% | 201 517 130 $ |
PURETECH HEALTH PLC 3,54% | 9 554 140 | 3,54% | 25 840 509 $ |
43 103 | 0,71% | 136 420 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Herbacos Recordati sro
Herbacos Recordati sro Household/Personal CareConsumer Non-Durables Part of CVC Advisers Ltd., Herbacos Recordati sro is a Czech company that manufactures and distributes cosmetic products. The company is located in Czechia. |
Household/Personal Care
|
Recordati AG
Recordati AG Drugstore ChainsRetail Trade Recordati AG engages in the trading in as well as importation and exportation of pharmaceutical, biological, chemical, laboratory, and diagnostic products. It also provides consulting services in the areas of marketing and management, with focus on the pharmaceutical industry. The company was founded on June 8, 2011 and is headquartered in Baar, Switzerland. |
Drugstore Chains
|
Recordati Ilac San ve Tic AS
| |
Recordati BVBA
Recordati BVBA Medical DistributorsDistribution Services Part of CVC Advisers Ltd., Recordati BV is a trading brokerage in pharmaceutical products and orthopedic articles. The company is located in Belgium. |
Medical Distributors
|
Recordati Ireland Ltd.
Recordati Ireland Ltd. Pharmaceuticals: MajorHealth Technology Recordati Ireland Ltd. manufactures pharmaceutical products. It offers pharmaceuticals in the therapeutic areas of cardiovascular, antibiotics and antivirals, central nervous system, gastroenterology, dermatological, muscolo-skeletal disorders, genito-urinary system and pain therapy, obstetics and gynaecology and OTC (non-prescription pharmaceuticals). The company was founded in 2002 and is headquartered in Cork, Ireland. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+38,51 % | 727 Mrd. | |
+33,05 % | 599 Mrd. | |
-6,23 % | 354 Mrd. | |
+18,78 % | 328 Mrd. | |
+1,35 % | 277 Mrd. | |
+16,00 % | 243 Mrd. | |
+8,09 % | 205 Mrd. | |
-5,77 % | 203 Mrd. | |
+6,19 % | 164 Mrd. |
- Börse
- Aktien
- A0EABR Aktie
- A0EABR Aktie
- Unternehmen Recordati